Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too

High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now. [...]intellectual property rights will be a significant dete...

Full description

Saved in:
Bibliographic Details
Published in:BMJ global health 2021-04, Vol.6 (4), p.e005518
Main Authors: Perehudoff, Katrina, 't Hoen, Ellen, Boulet, Pascale
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Agreements
AIDS
Antiviral drugs
Biomedical Technology
Commentary
Coronaviruses
COVID-19
COVID-19 - prevention & control
Developed Countries
Global health
Health administration
health policy
Hepatitis
High income
Humans
Intellectual property
Inventors
Law
Licenses
Licensing
Low income groups
Medical technology
Negotiations
Pandemics
Patents as Topic
Patients
Prices
Property rights
R&D
Recovery (Medical)
Research & development
Technology, Pharmaceutical
vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b5192-89c0f92272ef5651c5d79d9f06713a818f7f4643a12095a11dd41fc5a582a7863
cites cdi_FETCH-LOGICAL-b5192-89c0f92272ef5651c5d79d9f06713a818f7f4643a12095a11dd41fc5a582a7863
container_end_page
container_issue 4
container_start_page e005518
container_title BMJ global health
container_volume 6
creator Perehudoff, Katrina
't Hoen, Ellen
Boulet, Pascale
description High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now. [...]intellectual property rights will be a significant determinant of global access to COVID-19 medicines. [...]in these countries, prices are high and supplies are limited by Gilead’s exclusive patent rights and its finite capacity to manufacture the medicine. [...]in 2017 the US state of Louisiana explored its options to leverage a government use provision in state law to lower the price of the expensive hepatitis C treatments sofosbuvir and ledipasvir/sofosbuvir.10 Although the government use provision was not invoked in the end, it was an effective negotiation strategy with the pharmaceutical manufacturer that eventually led to a more affordable ‘netflix’ (or subscription-based payment) model for buying these hepatitis C drugs.11 Recently, government use licensing in the UK (called ‘Crown use’) has garnered much political and public attention following the rationing of lifesaving medicines due to their escalating prices.
doi_str_mv 10.1136/bmjgh-2021-005518
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3053c4ac2d634e768598ea4376f95886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3053c4ac2d634e768598ea4376f95886</doaj_id><sourcerecordid>2560017204</sourcerecordid><originalsourceid>FETCH-LOGICAL-b5192-89c0f92272ef5651c5d79d9f06713a818f7f4643a12095a11dd41fc5a582a7863</originalsourceid><addsrcrecordid>eNqNkkuLFDEUhQtRnGGcH-BGAm5cTGkelZcLYRh8DAzMRtchnUd1mqqkTaoa-t-b7hrbGUFwk4Sb7x5Obk7TvEbwPUKEfViNm37dYohRCyGlSDxrzjGksuUSiuePzmfNZSkbCCHidYHsZXNGiMCcS3Le7O53LudgQ-yBzXMPdLRgdDYYPYDJmXVMQ-r3YKsnF6cCfMr1HK0bgwHZmVTb9x-BBoPrwxTGioGxFo_gOlSHIZo0OmDSHKccXLkCU0qvmhdeD8VdPuwXzY8vn7_ffGvv7r_e3lzftSuKJG6FNNBLjDl2njKKDLVcWukh44hogYTnvmMd0QhDSTVC1nbIG6qpwJoLRi6a20XXJr1R21wN5r1KOqhjIeVe6TwFMzhFICWm0wZbRjrHmaBSON0Rzryk4qj1adHazqs6IVPnkfXwRPTpTQxr1aedEpAgiGEVePcgkNPP2ZVJjaEYNww6ujQXhWnFGEMdrujbv9BNmnOso6oUO3wlhl2l0EKZnErJzp_MIKgOIVHHkKhDSNQSktrz5vErTh2_I1GBqwWovf-l1_7BTyb_zf8CDlPULA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2560017204</pqid></control><display><type>article</type><title>Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too</title><source>BMJ Journals (Open Access)</source><source>PubMed Central</source><creator>Perehudoff, Katrina ; 't Hoen, Ellen ; Boulet, Pascale</creator><creatorcontrib>Perehudoff, Katrina ; 't Hoen, Ellen ; Boulet, Pascale</creatorcontrib><description>High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now. [...]intellectual property rights will be a significant determinant of global access to COVID-19 medicines. [...]in these countries, prices are high and supplies are limited by Gilead’s exclusive patent rights and its finite capacity to manufacture the medicine. [...]in 2017 the US state of Louisiana explored its options to leverage a government use provision in state law to lower the price of the expensive hepatitis C treatments sofosbuvir and ledipasvir/sofosbuvir.10 Although the government use provision was not invoked in the end, it was an effective negotiation strategy with the pharmaceutical manufacturer that eventually led to a more affordable ‘netflix’ (or subscription-based payment) model for buying these hepatitis C drugs.11 Recently, government use licensing in the UK (called ‘Crown use’) has garnered much political and public attention following the rationing of lifesaving medicines due to their escalating prices.</description><identifier>ISSN: 2059-7908</identifier><identifier>EISSN: 2059-7908</identifier><identifier>DOI: 10.1136/bmjgh-2021-005518</identifier><identifier>PMID: 33827793</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd</publisher><subject>Acquired immune deficiency syndrome ; Agreements ; AIDS ; Antiviral drugs ; Biomedical Technology ; Commentary ; Coronaviruses ; COVID-19 ; COVID-19 - prevention &amp; control ; Developed Countries ; Global health ; Health administration ; health policy ; Hepatitis ; High income ; Humans ; Intellectual property ; Inventors ; Law ; Licenses ; Licensing ; Low income groups ; Medical technology ; Negotiations ; Pandemics ; Patents as Topic ; Patients ; Prices ; Property rights ; R&amp;D ; Recovery (Medical) ; Research &amp; development ; Technology, Pharmaceutical ; vaccines</subject><ispartof>BMJ global health, 2021-04, Vol.6 (4), p.e005518</ispartof><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b5192-89c0f92272ef5651c5d79d9f06713a818f7f4643a12095a11dd41fc5a582a7863</citedby><cites>FETCH-LOGICAL-b5192-89c0f92272ef5651c5d79d9f06713a818f7f4643a12095a11dd41fc5a582a7863</cites><orcidid>0000-0003-3958-0244 ; 0000-0003-4477-6866</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://gh.bmj.com/content/6/4/e005518.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://gh.bmj.com/content/6/4/e005518.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27549,27550,27924,27925,53791,53793,55350,77473,77504,77532,77558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33827793$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perehudoff, Katrina</creatorcontrib><creatorcontrib>'t Hoen, Ellen</creatorcontrib><creatorcontrib>Boulet, Pascale</creatorcontrib><title>Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too</title><title>BMJ global health</title><addtitle>BMJ Glob Health</addtitle><addtitle>BMJ Global Health</addtitle><addtitle>BMJ Glob Health</addtitle><description>High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now. [...]intellectual property rights will be a significant determinant of global access to COVID-19 medicines. [...]in these countries, prices are high and supplies are limited by Gilead’s exclusive patent rights and its finite capacity to manufacture the medicine. [...]in 2017 the US state of Louisiana explored its options to leverage a government use provision in state law to lower the price of the expensive hepatitis C treatments sofosbuvir and ledipasvir/sofosbuvir.10 Although the government use provision was not invoked in the end, it was an effective negotiation strategy with the pharmaceutical manufacturer that eventually led to a more affordable ‘netflix’ (or subscription-based payment) model for buying these hepatitis C drugs.11 Recently, government use licensing in the UK (called ‘Crown use’) has garnered much political and public attention following the rationing of lifesaving medicines due to their escalating prices.</description><subject>Acquired immune deficiency syndrome</subject><subject>Agreements</subject><subject>AIDS</subject><subject>Antiviral drugs</subject><subject>Biomedical Technology</subject><subject>Commentary</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention &amp; control</subject><subject>Developed Countries</subject><subject>Global health</subject><subject>Health administration</subject><subject>health policy</subject><subject>Hepatitis</subject><subject>High income</subject><subject>Humans</subject><subject>Intellectual property</subject><subject>Inventors</subject><subject>Law</subject><subject>Licenses</subject><subject>Licensing</subject><subject>Low income groups</subject><subject>Medical technology</subject><subject>Negotiations</subject><subject>Pandemics</subject><subject>Patents as Topic</subject><subject>Patients</subject><subject>Prices</subject><subject>Property rights</subject><subject>R&amp;D</subject><subject>Recovery (Medical)</subject><subject>Research &amp; development</subject><subject>Technology, Pharmaceutical</subject><subject>vaccines</subject><issn>2059-7908</issn><issn>2059-7908</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>DOA</sourceid><recordid>eNqNkkuLFDEUhQtRnGGcH-BGAm5cTGkelZcLYRh8DAzMRtchnUd1mqqkTaoa-t-b7hrbGUFwk4Sb7x5Obk7TvEbwPUKEfViNm37dYohRCyGlSDxrzjGksuUSiuePzmfNZSkbCCHidYHsZXNGiMCcS3Le7O53LudgQ-yBzXMPdLRgdDYYPYDJmXVMQ-r3YKsnF6cCfMr1HK0bgwHZmVTb9x-BBoPrwxTGioGxFo_gOlSHIZo0OmDSHKccXLkCU0qvmhdeD8VdPuwXzY8vn7_ffGvv7r_e3lzftSuKJG6FNNBLjDl2njKKDLVcWukh44hogYTnvmMd0QhDSTVC1nbIG6qpwJoLRi6a20XXJr1R21wN5r1KOqhjIeVe6TwFMzhFICWm0wZbRjrHmaBSON0Rzryk4qj1adHazqs6IVPnkfXwRPTpTQxr1aedEpAgiGEVePcgkNPP2ZVJjaEYNww6ujQXhWnFGEMdrujbv9BNmnOso6oUO3wlhl2l0EKZnErJzp_MIKgOIVHHkKhDSNQSktrz5vErTh2_I1GBqwWovf-l1_7BTyb_zf8CDlPULA</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Perehudoff, Katrina</creator><creator>'t Hoen, Ellen</creator><creator>Boulet, Pascale</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3958-0244</orcidid><orcidid>https://orcid.org/0000-0003-4477-6866</orcidid></search><sort><creationdate>20210401</creationdate><title>Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too</title><author>Perehudoff, Katrina ; 't Hoen, Ellen ; Boulet, Pascale</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b5192-89c0f92272ef5651c5d79d9f06713a818f7f4643a12095a11dd41fc5a582a7863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Agreements</topic><topic>AIDS</topic><topic>Antiviral drugs</topic><topic>Biomedical Technology</topic><topic>Commentary</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention &amp; control</topic><topic>Developed Countries</topic><topic>Global health</topic><topic>Health administration</topic><topic>health policy</topic><topic>Hepatitis</topic><topic>High income</topic><topic>Humans</topic><topic>Intellectual property</topic><topic>Inventors</topic><topic>Law</topic><topic>Licenses</topic><topic>Licensing</topic><topic>Low income groups</topic><topic>Medical technology</topic><topic>Negotiations</topic><topic>Pandemics</topic><topic>Patents as Topic</topic><topic>Patients</topic><topic>Prices</topic><topic>Property rights</topic><topic>R&amp;D</topic><topic>Recovery (Medical)</topic><topic>Research &amp; development</topic><topic>Technology, Pharmaceutical</topic><topic>vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perehudoff, Katrina</creatorcontrib><creatorcontrib>'t Hoen, Ellen</creatorcontrib><creatorcontrib>Boulet, Pascale</creatorcontrib><collection>BMJ Journals (Open Access)</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMJ global health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perehudoff, Katrina</au><au>'t Hoen, Ellen</au><au>Boulet, Pascale</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too</atitle><jtitle>BMJ global health</jtitle><stitle>BMJ Glob Health</stitle><stitle>BMJ Global Health</stitle><addtitle>BMJ Glob Health</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>6</volume><issue>4</issue><spage>e005518</spage><pages>e005518-</pages><issn>2059-7908</issn><eissn>2059-7908</eissn><abstract>High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now. [...]intellectual property rights will be a significant determinant of global access to COVID-19 medicines. [...]in these countries, prices are high and supplies are limited by Gilead’s exclusive patent rights and its finite capacity to manufacture the medicine. [...]in 2017 the US state of Louisiana explored its options to leverage a government use provision in state law to lower the price of the expensive hepatitis C treatments sofosbuvir and ledipasvir/sofosbuvir.10 Although the government use provision was not invoked in the end, it was an effective negotiation strategy with the pharmaceutical manufacturer that eventually led to a more affordable ‘netflix’ (or subscription-based payment) model for buying these hepatitis C drugs.11 Recently, government use licensing in the UK (called ‘Crown use’) has garnered much political and public attention following the rationing of lifesaving medicines due to their escalating prices.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd</pub><pmid>33827793</pmid><doi>10.1136/bmjgh-2021-005518</doi><orcidid>https://orcid.org/0000-0003-3958-0244</orcidid><orcidid>https://orcid.org/0000-0003-4477-6866</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2059-7908
ispartof BMJ global health, 2021-04, Vol.6 (4), p.e005518
issn 2059-7908
2059-7908
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3053c4ac2d634e768598ea4376f95886
source BMJ Journals (Open Access); PubMed Central
subjects Acquired immune deficiency syndrome
Agreements
AIDS
Antiviral drugs
Biomedical Technology
Commentary
Coronaviruses
COVID-19
COVID-19 - prevention & control
Developed Countries
Global health
Health administration
health policy
Hepatitis
High income
Humans
Intellectual property
Inventors
Law
Licenses
Licensing
Low income groups
Medical technology
Negotiations
Pandemics
Patents as Topic
Patients
Prices
Property rights
R&D
Recovery (Medical)
Research & development
Technology, Pharmaceutical
vaccines
title Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A59%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overriding%20drug%20and%20medical%20technology%20patents%20for%20pandemic%20recovery:%20a%20legitimate%20move%20for%20high-income%20countries,%20too&rft.jtitle=BMJ%20global%20health&rft.au=Perehudoff,%20Katrina&rft.date=2021-04-01&rft.volume=6&rft.issue=4&rft.spage=e005518&rft.pages=e005518-&rft.issn=2059-7908&rft.eissn=2059-7908&rft_id=info:doi/10.1136/bmjgh-2021-005518&rft_dat=%3Cproquest_doaj_%3E2560017204%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b5192-89c0f92272ef5651c5d79d9f06713a818f7f4643a12095a11dd41fc5a582a7863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2560017204&rft_id=info:pmid/33827793&rfr_iscdi=true